Compounded semaglutide with cyanocobalamin is a pharmacy-prepared injectable that combines semaglutide, a GLP-1 receptor agonist, with cyanocobalamin, a synthetic form of vitamin B12. It is prepared by compounding pharmacies for individual patients pursuant to a prescription and is not an FDA-approved drug product.
Among clinics ordering through ScriptLinkRx, semaglutide with cyanocobalamin ranks as the #4 most-prescribed compounded product, based on cumulative order volume across clinics ordering through ScriptLinkRx as of mid-2026. Its position reflects broader demand from weight-management and metabolic-health practices — but it also sits in one of the most actively regulated corners of pharmacy compounding. Providers prescribing this formulation in 2026 need a working understanding of the "essentially a copy" framework, the FDA's position on additives, and what to require from a compounding pharmacy.
What Semaglutide with Cyanocobalamin Is
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Pharmacologically, GLP-1 receptor agonism is associated with glucose-dependent insulin secretion, slowed gastric emptying, and central appetite signaling. FDA-approved semaglutide products exist for type 2 diabetes and chronic weight management; compounded semaglutide is a distinct category of product that has not undergone FDA premarket review.
Cyanocobalamin is a synthetic, stable form of vitamin B12. Injectable cyanocobalamin has long been available as an FDA-approved product in its own right, indicated for vitamin B12 deficiency states such as pernicious anemia. In compounded formulations, it is co-formulated with semaglutide in a single injectable preparation.
The rationale some prescribers cite for the combination relates to nutritional status during GLP-1 therapy — for example, concerns about dietary intake or absorption in patients with reduced oral intake. It is important to state plainly that the FDA has not evaluated the combination: the agency has said the safety and effectiveness of semaglutide products that include additives such as cyanocobalamin have not been established, and that it has received adverse event reports associated with compounded semaglutide products generally. Whether a B12 additive is clinically justified for a given patient is a determination the prescriber — not the pharmacy, and not a marketing page — is responsible for making and documenting.
How Providers Use It in Practice
As of mid-2026, orders for semaglutide-cyanocobalamin formulations on ScriptLinkRx come predominantly from weight-management clinics, med spas operating under medical direction, and primary-care or endocrinology-adjacent practices that run metabolic health programs. Longevity and wellness practices also appear in the ordering mix.
In practice, some providers prescribe a combined semaglutide-B12 formulation in the context of:
- Weight-management programs where the prescriber has documented a patient-specific reason a commercially available semaglutide product is not appropriate for that patient, and has separately documented the clinical rationale for the B12 component.
- Patients with documented or suspected B12 insufficiency where the prescriber wants to address vitamin status alongside GLP-1 therapy rather than through a separate product — again, as a patient-specific judgment.
- Consolidated injection regimens, where a prescriber determines that a single co-formulated injection is preferable for a specific patient to two separate products.
Each of these is a hedged, individualized clinical decision. None of them functions as a blanket justification that can be applied to an entire patient panel — a point discussed further in the regulatory section below.
Forms and Combinations Available Through Compounding
Compounded semaglutide with cyanocobalamin is most commonly prepared as a sterile injectable solution for subcutaneous administration, typically dispensed in multi-dose vials with syringes supplied separately. Because these are pharmacy-prepared products, concentrations and container formats vary between pharmacies — a variability the FDA has specifically flagged as a source of dosing errors with compounded semaglutide, and a reason providers should confirm the exact concentration and labeling conventions of any product they prescribe.
Related compounded formulations in the same family include:
- Semaglutide co-formulated with pyridoxine — see compounded semaglutide with B6
- Semaglutide with other additives such as L-carnitine or NAD+, which some pharmacies offer and which face the same additive-justification scrutiny
- Tirzepatide-based analogues of the same concept — see compounded tirzepatide with B12
The traditional case for compounding — patient-specific customization that a manufactured product cannot provide — is the lens through which every one of these formulations should be evaluated. A compounded semaglutide-B12 product exists lawfully only where there is a legitimate, documented, individualized need. It does not exist as a general-purpose alternative to approved semaglutide products.
Regulatory Status and Provider Considerations
This is the compliance heart of the topic, and the facts have moved quickly. As of July 2026:
Compounded semaglutide is not FDA-approved. No compounded semaglutide product — with or without cyanocobalamin — has been reviewed by the FDA for safety, effectiveness, or quality, and compounded products are not equivalent to approved semaglutide products such as Ozempic, Wegovy, or Rybelsus.
The shortage is over, and the "essentially a copy" framework governs. The FDA declared the semaglutide shortage resolved in February 2025. During the shortage, compounders could prepare products that were essentially copies of the approved drugs; that flexibility ended with the shortage. The FDA's enforcement-discretion wind-down periods for 503A pharmacies and 503B outsourcing facilities expired in the spring of 2025. Today, a 503A pharmacy may compound a semaglutide product only when it is not "essentially a copy" of a commercially available drug — which, practically, requires a prescriber's documented determination that a specific change produces a significant difference for the identified patient.
An additive does not automatically solve the copy problem. Some have treated the inclusion of B12 as a formulaic way to differentiate a compounded product from the approved drugs. The FDA has stated it is aware that some compounders add ingredients such as cyanocobalamin, pyridoxine, levocarnitine, and NAD+ to semaglutide products, and that the safety and effectiveness of these combinations have not been established. A blanket, panel-wide rationale for an additive is exactly what the framework does not permit. The individualized-need justification is the provider's responsibility: the patient-specific reason for the additive should live in that patient's chart.
The 503B pathway is narrowing. In 2026, the FDA proposed excluding semaglutide (along with tirzepatide and liraglutide) from the 503B bulks list, which — if finalized — would foreclose outsourcing facilities from compounding these drugs from bulk substance. Providers sourcing from 503B facilities should track this proceeding closely, as it directly affects supply continuity planning.
Only the base form of semaglutide is appropriate for compounding. The FDA has warned that some products have been made with salt forms (semaglutide sodium, semaglutide acetate), which are different active ingredients than the semaglutide base used in the approved drugs and do not meet the conditions for compounding. Providers should confirm their pharmacy compounds exclusively from semaglutide base.
Dosing-error reports are a documented risk area. The FDA has alerted providers and compounders to adverse events tied to dosing errors with compounded injectable semaglutide, driven largely by variable concentrations and container types. Clear labeling, consistent concentration, and unambiguous patient-facing instructions from the dispensing pharmacy are risk-management essentials.
Sourcing and Quality: What to Ask a Compounding Pharmacy
Before prescribing any compounded semaglutide-B12 product, providers should be able to get satisfactory answers to the following:
- API source and documentation. Is the semaglutide API the base form (not a salt), sourced from an FDA-registered facility, with lot-specific Certificates of Analysis available for both the semaglutide and cyanocobalamin components?
- Facility type and licensure. Is the pharmacy a 503A pharmacy or a 503B outsourcing facility? Is it licensed in the state where the patient resides, and can it produce current state board standing?
- Sterile compounding compliance. Does the facility document compliance with USP <797> for sterile preparations (and USP <795>/<800> where applicable), including environmental monitoring records?
- Potency and sterility testing. Is finished-product testing performed — potency, sterility, and endotoxin — and are results available per batch?
- Beyond-use dating. How is the BUD established for the combined formulation, and is it supported by stability data rather than default assumptions? Co-formulated products raise stability questions that single-ingredient products do not.
- Labeling and concentration practices. Does the pharmacy dispense at a consistent concentration with labeling that supports accurate dose measurement, given the FDA's documented dosing-error concerns?
Clinics ordering compounded medications through platforms like ScriptLinkRx work with partner pharmacies that are vetted on these dimensions, but the questions above remain the prescriber's to ask — sourcing diligence is not delegable.
Frequently Asked Questions
Is compounded semaglutide with B12 FDA-approved?
No. No compounded drug is FDA-approved. FDA-approved semaglutide products exist, and injectable cyanocobalamin exists as an approved product for B12 deficiency, but the compounded combination has not been reviewed by the FDA for safety, effectiveness, or quality.
Can a 503A pharmacy still compound semaglutide with B12 after the shortage resolution?
Only within the "essentially a copy" framework. As of July 2026, that generally requires a prescriber's documented, patient-specific determination that the compounded formulation produces a significant clinical difference for that individual patient. The presence of B12 in the formula does not by itself satisfy that requirement.
What documentation should a prescriber maintain for the B12 additive?
The patient-specific clinical rationale — for example, documented B12 status or an individualized reason the combined product is appropriate for that patient — should be recorded in the chart and reflected on the prescription. FDA has questioned blanket rationales for additives, so the justification must be individualized, and it is the provider's responsibility.
How is semaglutide-B12 different from semaglutide with B6?
The GLP-1 component and the regulatory framework are the same; the additive differs (cyanocobalamin versus pyridoxine), and so does the patient-specific rationale a prescriber would document. See the companion overview of compounded semaglutide with B6 for that formulation.
Related Reading
- See where semaglutide with B12 ranks among the most-prescribed compounded medications
- Compounded semaglutide with B6 (pyridoxine)
- Compounded tirzepatide with B12
Sources
- FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
- FDA: Declaratory Order — Resolution of Shortages of Semaglutide Injection Products
- FDA: FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products
- FDA: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
